ReviewDiscover oncology2025
Immunological factors underlying radiation-induced toxicity in prostate cancer patients: a systematic review.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiotherapy (RT) represents a well-established treatment modality for patients diagnosed with prostate cancer. Despite a low toxicity profile, a small proportion of patients suffer long-term effects with a decrease in quality of life. Several risk factors for the prediction of radiation-induced toxicity have been evaluated. This study aimed to systematically review the current literature on the immunological factors underlying radiation-induced toxicity in prostate cancer patients undergoing RT.
methodsA comprehensive search in three databases (PubMed, Web of Science, Scopus) was conducted. Eligible papers reported on toxicity and immunological factors in patients treated with RT with curative intent. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed in each step. The quality of the included articles was assessed utilizing the Newcastle Ottawa Quality Assessment Scale (NOS).
resultsA total of 15 studies, encompassing 1237 patients, were included, with a median age ranging from 62 to 74 years. Ten studies reported on primary RT only, while five assessed both primary and postoperative RT. Tumor stage and lymph node involvement varied among studies. Utilized radiation treatment modalities were intensity-modulated radiotherapy, stereotactic body radiotherapy, three-dimensional conventional radiotherapy, and low-dose rate brachytherapy. Androgen deprivation therapy was administered and reported inconsistently. Immunological factors and assessed toxicities varied between studies. Thus, reports on immunological factors and predictive biomarkers remain scarce and inconclusive. Besides lymphocyte counts, the most common molecules that significantly correlated with RT-induced toxicity in prostate cancer patients were interleukin-6 (IL-6), interleukin-2 (IL-2), tumor necrosis factor-α (TNF-α), and transforming growth factor-β1 (TGF-β1).
conclusionPublications on immunological factors as predictors of RT-induced toxicity remain rare and exhibit a high degree of variability in treatment, toxicity, and immunological factor assessment. Yet, IL-6, IL-2, TNF-α, and lymphocyte counts are the most consistent markers for predicting toxicity in prostate cancers post-RT. Future preclinical and clinical studies should corroborate these findings, with the final goal of improving patient treatment outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.